An additional piece of the puzzle in determining how c-myc exerts its immune inhibitory activities was provided when Schlee et al. [86] demonstrated that c-myc overexpression alters mRNA profiles in conditional B-cell lymphoma lines via the NFκB activation pathway (Table 1). Here, MYC is linked to B-cell non-Hodgkin lymphoma.